Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Lauren Pachman¹, Wil Marin ², Gabrielle Morgan ¹, Megan L. Curran ³, Kaveh Ardalan ⁴, Chiang-Ching Huang ⁵ and Eli Roberson ⁶, ¹Northwestern University, Chicago, ²Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, ³University of Colorado, Aurora, CO, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵University of Milwaukee, Milwaukee, WI, ⁶Washington University at St.Louis, St.Louis, MO
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…
Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Fabrizio De Benedetti¹, Inmaculada Calvo Penadés ², Nadina Rubio-Pérez ³, Alexey Maschan ⁴, Pierre Quartier ⁵, Zbigniew Żuber ⁶, Marina Stanislav ⁷, Raul Barria ⁸, Daniel Clemente ⁹, Gabriel Vega-Cornejo ¹⁰, Nancy Liu ¹¹, Christine Xu ¹¹, Angeliki Giannelou ¹², Bolanle Akinlade ¹² and Lydie Baret-Cormel ¹³, ¹Bambino Gesù Children’s Hospital, Rome, Italy, ²Hospital Univ. La Fe, Valencia, Spain, ³University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ⁴Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ⁵Necker Hospital, Paris, France, ⁶Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸Bioreuma, Concepción, Chile, ⁹Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ¹⁰CREA de Guadalajara, Jalisco, Mexico, ¹¹Sanofi, Bridgewater, NJ, ¹²Regeneron, New York, NY, ¹³Sanofi, Chilly-Mazarin, France
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
Abstract Number: 1724 • 2019 ACR/ARP Annual Meeting
Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Brandi Stevens¹, Martha Rodriquez ¹, Amy Rakestraw ² and Kathleen O'Neil ¹, ¹Indiana University, Indianapolis, IN, ²Indiana University Health, Indianapolis, IN
Background/Purpose: Systemic Lupus Erythematosus (SLE) can be a severe disease, especially when diagnosed in childhood. Onset prior to puberty (Tanner stage II) is rare, and…
Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Rebecca Overbury¹, Aimee Hersh ², CJ Inman ², Sara Stern ², Karen James ² and John Bohnsack ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
Abstract Number: 1728 • 2019 ACR/ARP Annual Meeting
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Anthony Hoang ¹, Howard Yang ², Tracy Andrews ³, Jennifer Weiss ⁴, Kathleen Haines ⁴, Yukiko Kimura ⁵ and Suzanne Li⁴, ¹Rutgers University, New Brunswick, NJ, ²David Geffen School of Medicine at UCLA, Santa Monica, CA, ³Rutgers University, Newark, NJ, ⁴Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH
Background/Purpose: Avascular necrosis (AVN) is a serious comorbidity of juvenile systemic lupus erythematosus (jSLE) associated with disability, impaired quality of life, and increased cost of…
Abstract Number: 2719 • 2019 ACR/ARP Annual Meeting
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Rebecca Sadun¹, Amanda Eudy ¹, Peter Chiraseveenuprapund ², Cuoghi Edens ³, Aimee Hersh ⁴, Kiana Johnson ⁵ and Erica Lawson ⁶, ¹Duke University, Durham, ²UCSD, San Diego, CA, ³University of Chicago, Chicago, IN, ⁴University of Utah, Salt Lake City, UT, ⁵East Tennessee, Johnson City, TN, ⁶University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
Background/Purpose: The transition from pediatric to adult-oriented health care represents a vulnerable period for young adults with chronic rheumatic diseases. In spite of this, a…
Abstract Number: 1746 • 2019 ACR/ARP Annual Meeting
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Elizabeth Sloan¹, Tracey Wright ¹ and Yu Zuo ², ¹University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, ²University of Texas Southwestern, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (aPL) have been extensively reported in children; however, research on thrombotic risks associated with aPL among pediatric patients is scarce. Positive aPL…
Abstract Number: 2721 • 2019 ACR/ARP Annual Meeting
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ², Elizabeth Mendoza ², Kimberly S. Miller ³, Nina H. Thomas ¹, Pamela F. Weiss ¹, David D. Sherry ¹ and Jeffrey Gerber ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital fo Philadelphia, Philadelphia, PA
Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this…
Abstract Number: 1747 • 2019 ACR/ARP Annual Meeting
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Audrea Chen¹, Cherry Mammen ¹, Jaime Guzman ², David Cabral ² and Kimberly Morishita ¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is common in ANCA-associated vasculitis (AAV) and one of the goals of early treatment is to maximize renal function recovery. Corticosteroids are…
Abstract Number: 2722 • 2019 ACR/ARP Annual Meeting
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Jordan Jones¹, Daniel J. Lovell ², Chelsey Smith ³ and Mara Becker ⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³Children's Mercy Kansas City, Kansas, MO, ⁴Duke Children's Hospital, Durham, NC
Background/Purpose: Down syndrome arthropathy (DA) is under-recognized with a 19-month average delay in diagnosis (1). The majority present with polyarticular, rheumatoid factor (RF) and anti-nuclear…
Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Sara Patrizi¹, Douglas Stram ², Miranda Weintraub ³ and Alexandra Aminoff ¹, ¹Kaiser Permanente, Department of Pediatrics, Oakland, ²Kaiser Permanente Northern California, Division of Research, Oakland, ³Kaiser Permanente, Department of Graduate Medical Education, Oakland
Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Bhargavi Duvvuri¹, Lauren Pachman ², Richard Moore ¹, Gabrielle Morgan ², Marisa Klein-Gitelman ², Megan L. Curran ³, Stephen Doty ⁴ and Christian Lood ¹, ¹University of Washington, Seattle, ²Northwestern University, Chicago, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…
Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
edoardo marrani¹, Sarah Abu Rumeileh ¹, Francesca Tirelli ², Ilaria Maccora ³ and Gabriele Simonini ⁴, ¹Post graduate School of pediatrics, University of Florence, Firenze, Italy, ²Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, ³Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, ⁴Anna Meyer Children's Hospital, Flotence, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino¹, Damon L Bass ², Gina Eriksson ¹, Anne Hammer ¹, Beulah Ji ³, Holly Quasny ⁴ and David Roth ⁵, ¹GlaxoSmithKline, Collegeville, ²GlaxoSmithKline, Collegeville, PA, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, ⁵GSK, Collegeville, PA
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…
Abstract Number: 1753 • 2019 ACR/ARP Annual Meeting
Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?
Lily SH Lim¹, Okechukwu Ekuma ², Ruth Ann Marrie ¹, Marni Brownell ², Christine Peschken ¹, Carol Hitchon ¹, Kerstin Gerhold ¹ and Lisa Lix ³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Center for Health Policy, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, Canada
Background/Purpose: Youths with childhood-onset chronic rheumatic diseases (ChildCRD), including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD), have worse grade 12 standards tests results…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].